Olema Pharmaceuticals, Inc. filings document the regulatory record of a clinical-stage oncology company with common stock listed on the Nasdaq Global Select Market under OLMA. The company’s disclosures cover its targeted-therapy pipeline, including palazestrant and OP-3136, as well as financial results, liquidity updates, capital-structure matters, and Regulation FD investor materials.
Olema’s SEC filings also record material agreements, including lease arrangements, and governance matters such as board appointments, officer departures, indemnification agreements, compensation arrangements, and equity awards. Proxy materials address director elections, executive compensation, equity incentive plans, pay-versus-performance disclosure, and shareholder voting matters.
Olema Oncology reported fourth-quarter and full-year 2025 results, highlighting progress in its breast cancer pipeline and a stronger balance sheet. The company raised approximately $218.5 million in a follow-on offering and ended 2025 with $505.4 million in cash, cash equivalents, and marketable securities.
Net loss widened to $46.1 million for the quarter and $162.5 million for the year, mainly from higher research and development and corporate spending as Phase 3 trials for palazestrant and a Phase 1 study for OP-3136 advanced. Non-GAAP R&D and G&A expenses also increased as Olema built late-stage and future commercial capabilities.
The company expects initial OP-3136 clinical data in Q2 2026 and top-line Phase 3 OPERA-01 results for palazestrant in the fall of 2026, while preparing for a potential first commercial launch in late 2027.
OLMA insider filed a Form 144 proposing the sale of 50,000 shares of Common Stock. The filing lists an option-originated sale of $50,000 shares scheduled 03/11/2026 and shows multiple reported dispositions by Shane W. Kovacs in the prior three months, including 241,999 shares sold on 03/09/2026 and other sales dated between 01/13/2026 and 03/10/2026.
The entries show per-transaction cash proceeds for each sale; the filing records the sales as cash transactions and identifies Fidelity Brokerage Services LLC as a broker for an earlier position. This Form 144 documents proposed and recent insider sales rather than a company capital-raising action.
Shane W. Kovacs reported sales of Common Stock as shown on a Form 144. The filing lists multiple dispositions, including 100,000 shares on 01/15/2026 and 241,999 shares on 03/09/2026. The table shows share counts and gross proceeds for each sale between 01/13/2026 and 03/09/2026.
OLMA filed a Form 144 reporting proposed and completed sales of common stock by an affiliate. The filing lists proposed option-related sales dated 03/09/2026 (noting line items of 162,000 and 79,999 shares) and shows Shane W. Kovacs reported sales totaling 190,343 shares across dates from 01/13/2026 to 03/04/2026.
OLEMA PHARMACEUTICALS INC reports FMR LLC beneficial ownership of 9,998,059.72 shares of common stock, representing 12.5% of the class. The filing (Amendment No. 1 to a Schedule 13G) shows FMR LLC has sole dispositive power for 9,998,059.72 shares and sole voting power of 9,985,722 shares.
Abigail P. Johnson is also listed with sole dispositive power for 9,998,059.72 shares. The filing notes that one or more other persons have rights to dividends or proceeds but no other single person holds over 5%.
Olema Pharmaceuticals’ chief legal officer Mitchell Shawnte reported option exercises and related stock sales. On March 3–4, 2026, she exercised options for a total of 40,000 shares of common stock at $4.37 per share and sold 40,000 shares in open-market transactions at weighted average prices around the mid‑$20s. Following these trades, she reported 410,000 stock options outstanding and no directly held common shares.
Olma Health affiliate transactions: Shane W. Kovacs reported multiple sales of Common stock totaling several tranches in January–February 2026. The filing lists individual sales such as 100,000 shares on 01/15/2026 and smaller tranches on other dates, with cash proceeds shown per trade.
Shawnte M. Mitchell reported insider transactions related to common stock of the issuer. The filing shows a sale of 15,000 common shares on 03/03/2026 for $345,153. It also lists a proposed sale of 25,000 common shares through Fidelity Brokerage Services LLC on 03/04/2026, arising from an option granted on 02/28/2025, to be sold for cash.
Shane W. Kovacs reported proposed sales of Common Stock on Form 144 handled through Fidelity Brokerage Services LLC. The filing lists recent dispositions in the past three months: 01/15/2026 sale of $2,873,214.99 (100,000 shares), 02/23/2026 sale of $723,007.46 (30,000 shares), 02/24/2026 sale of $500,002.00 (20,000 shares), 02/12/2026 sale of $238,498.19 (10,000 shares) and an earlier 01/13/2026 entry of $107,069.20 (3,822 shares). The filing identifies the broker as Fidelity Brokerage Services LLC.